SCHEMBL2962185

SCHEMBL2962185

O=C(O)C=CC(=O)OCC(c1ccccc1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 10/20 0.59
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
LMNA P02545 4/20 0.46
MAPT P10636 2/20 0.46
MDM4 O15151 1/20 0.46
MDM2 Q00987 1/20 0.46
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28803459 1.00 HCAR2 (0.59) HCAR2CA12CA1CA2CA9
SCHEMBL2962180 0.94 CA12 (0.52) HCAR2CA12CA1CA2CA9
SCHEMBL28803458 0.94 CA12 (0.52) HCAR2CA12CA1CA2CA9
SCHEMBL3169558 0.80 THRB (0.53) HCAR2CA12CA1CA2CA9
SCHEMBL27576539 0.79 HCAR2 (0.49) HCAR2LMNAMAPTMDM4MDM2
SCHEMBL3235281 0.78 HCAR2 (0.54) HCAR2LMNAMAPTMDM4MDM2
SCHEMBL11385770 0.77 CA12 (0.57) CA12CA1CA2CA9LMNA
SCHEMBL11244962 0.77 CA12 (0.57) CA12CA1CA2CA9LMNA
SCHEMBL11244967 0.77 CA12 (0.57) CA12CA1CA2CA9LMNA
Cyanide SCHEMBL28037734 0.76 THRB (0.49) HCAR2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763263-B2 Skin external agents and drugs KAO CORPORATION (JP) 2010-07-27 US disclosed
EP-1249237-B1 Topical cosmetic and pharmaceutical composition comprising specific alkoxylated diester of fumaric acid KAO CORP (JP) 2007-07-18 EP disclosed
US-20060177408-A1 Skin external agents and drugs KANEBO COSTMETICS INC. 2006-08-10 US disclosed
US-7037489-B2 Skin external agents and drugs KANEBO COSMETICS, INC. (JP) 2006-05-02 US disclosed
US-20030185786-A1 Skin external agents and drugs KAO CORPORATION (JP) 2003-10-02 US disclosed
EP-1249237-A1 SKIN EXTERNAL AGENTS AND DRUGS Kanebo Limited (JP) 2002-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060177408-A1 Skin external agents and drugs CUTA, F12, NFE2 HCAR2 452/4885CA12 367/4885CA1 1079/4885
US-20030185786-A1 Skin external agents and drugs AREG, RARG, FRG1 HCAR2 191/4885CA12 1743/4885CA1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.